Industry news that matters to you.  Learn more

Archives for May 2014

Veracyte, Inc. Launches Afirma Malignancy Classifiers to Further Help Thyroid Nodule Patients Avoid Unnecessary Surgeries and Lower Healthcare Costs

Veracyte, Inc. (Nasdaq: VCYT) recently announced the launch of its Afirma Malignancy Classifiers to further establish the Afirma Thyroid FNA Analysis as a comprehensive tool for reducing unnecessary surgeries and healthcare costs among the more than 525,000 U.S. patients each year who undergo fine needle aspiration (FNA) biopsies to rule out cancer in thyroid nodules. The Afirma Malignancy Classifiers comprise genomic tests for medullary thyroid cancer (MTC) and the BRAF gene mutation and are intended to provide preoperative information to help guide surgical strategy for those patients who need surgery.

Luminex Corporation Announces Group B Streptococcus (GBS), as a Launch Menu Assay for its New Sample-to-Answer System, ARIES

Luminex Corporation (NASDAQ: LMNX) recently announced that Group B Streptococcus (group B strep, GBS) is the fifth assay planned for the launch menu of its new sample-to-answer system, ARIES™. The assay will complement Luminex’s growing portfolio of ASR and IVD products. Previously announced items in the five assay launch menu targeted for the ARIES system include: Flu A/B and RSV, HSV 1&2, Norovirus, and Clostridium difficile (C. diff).

North Shore Hematology Oncology Associates Partners With Caris Life Sciences to Establish a Personalized Cancer Care Program

North Shore Hematology Oncology Associates (NSHOA) and Caris Life Sciences recently announced a collaboration to establish a personalized cancer care program for patients in the greater Long Island area. This program will leverage the power of Caris Molecular Intelligence™, the industry’s leading comprehensive tumor profiling service, to better target therapy options based on each patient’s unique cancer biology.

Provectus Biopharmaceuticals Inc. to List on NYSE MKT

Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that its shares of common stock have been approved for listing on the NYSE MKT. Shares will begin trading on the NYSE MKT on Friday May 16, 2014. The company’s ticker symbol will remain “PVCT” but it will withdraw its shares from quotation on the OTCQB concurrent with listing its shares on the NYSE MKT.

Castle Biosciences’ Esophageal Cancer Test Identifies Patients Who Are Resistant to Standard Pre-Surgical Chemoradiation Therapy

Castle Biosciences Inc. announced that data from two clinical validation studies of its DecisionDx-EC multi-biomarker test were reviewed in an oral presentation at the Digestive Disease Week (DDW) Annual Meeting. The data show that the test accurately predicts response to pre-surgical chemoradiation therapy (CTRT) in patients with esophageal adenocarcinoma (EC). Also at the meeting, the Company presented initial data using the same biomarker panel to predict extreme resistance to chemoradiation in the treatment of rectal cancer.